Similar articles

• Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.

  Dohn LH, Jensen BV, Larsen FO. Dohn LH, et al. Acta Oncol. 2010 Apr;49(3):395-6. doi: 10.3109/02841860903428184. Acta Oncol. 2010. PMID: 20001495 No abstract available.
• Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.

  Saif MW, Merritt J, Robbins J, Stewart J, Schupp J. Saif MW, et al. Clin Colorectal Cancer. 2006 Sep;6(3):229-34. doi: 10.3816/CCC.2006.n.042. Clin Colorectal Cancer. 2006. PMID: 17026795 No abstract available.
• Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.

  Kabbinavar F, Kozloff M. Kabbinavar F, et al. Oncology. 2011;80(1-2):135-7; author reply 140-1. doi: 10.1159/000327227. Epub 2011 Jun 15. Oncology. 2011. PMID: 21677459 No abstract available.
• [Progress of chemotherapy in colorectal cancer].

  Komatsu Y. Komatsu Y. Gan To Kagaku Ryoho. 2007 Nov;34(11):1771-6. Gan To Kagaku Ryoho. 2007. PMID: 18064761 Review. Japanese. No abstract available.
• [Advances in the treatment of metastatic colorectal cancer with bevacizumab].

  Longo F, Mansueto G. Longo F, et al. Tumori. 2006 Sep-Oct;92(5):suppl 1-12. Tumori. 2006. PMID: 17168449 Review. Italian. No abstract available.